Bacterial and Fungal Infections in the Neonate: Current Diagnosis and Therapy

  • Pablo J. Sánchez
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)


A positive blood culture with a clinically recognized pathogen remains the gold standard for the diagnosis of neonatal sepsis. Debate continues as to whether multiple blood cultures should be performed. Certainly with bacterial organisms that are frequent blood culture contaminants, such as coagulase-negative staphylococci (CoNS), the diagnosis of sepsis is best confirmed by the finding of two or more positive cultures from multiple sites or body fluids that are normally sterile. The isolation of CoNS from only one blood culture when only one is obtained is problematic and of uncertain significance. Since many of these positive cultures represent contamination with skin microflora, the practice of obtaining only one blood culture often leads to prolonged and unnecessary antibiotic therapy. In our neonatal intensive care unit (NICU) at Parkland Memorial Hospital (PMH) in Dallas, Texas, we routinely obtain two blood cultures from all infants who are evaluated for possible sepsis.


Blood Culture Neonatal Intensive Care Unit Bloodstream Infection Positive Blood Culture Empiric Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Benjamin, D.K., Jr., Miller, W., Garges, H., Benjamin, D.K., McKinney, R.E., Jr., Cotton, M. et al. (2001). Bacteremia, central catheters, and neonates: When to pull the line. Pediatrics 107, 1272–1276.PubMedCrossRefGoogle Scholar
  2. Bryan, C.S., John, J.F., Jr., Pai, M.S., and Austin, T.L. (1985). Gentamicin vs cefotaxime for therapy of neonatal sepsis. Am. J. Dis. Child 139, 1086–1089.PubMedGoogle Scholar
  3. Butler, K.M., Rench, M.A., and Baker, C.J. (1990). Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr. Infect. Dis. J. 9, 51–56.PubMedCrossRefGoogle Scholar
  4. Dato, V.M. and Dajani, A.S. (1990). Candidemia in children with central venous catheters: Role of catheter removal and amphotericin B therapy. Pediatr. Infect. Dis. J. 9, 309–314.PubMedCrossRefGoogle Scholar
  5. de Man, P., Verhoeven, B.A., Verbrugh, H.A., Vos, M.C., and van den Anker, J.N. (2000). An antibiotic policy to prevent emergence of resistant bacilli. Lancet 355, 973–978.PubMedCrossRefGoogle Scholar
  6. Eppes, S.C., Troutman, J.L., and Gutman, L.T. (1989). Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr. Infect. Dis. J. 8, 99–104.PubMedCrossRefGoogle Scholar
  7. Franz, A.R., Steinbach, G., Kron, M., and Pohlandt, F. (1999). Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics 104, 447–453.PubMedCrossRefGoogle Scholar
  8. Hengst, J.M. (2003). The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv. Neonatal Care 3, 3–13.PubMedCrossRefGoogle Scholar
  9. Jackson, G.L., Sendelbach, D.M., Stehel, E.K., Baum, M., Manning, M.D., and Engle, W.D. (2003). Association of hypocalcemia with a change in gentamicin administration in neonates. Pediatr. Nephrol. 18, 653–656.PubMedGoogle Scholar
  10. Karlowicz, M.G., Hashimoto, L.N., Kelly, R.E., Jr., and Buescher, E.S. (2000a). Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 106, E63.PubMedCrossRefGoogle Scholar
  11. Karlowicz, M.G., Buescher, E.S., and Surka, A.E. (2000b). Fulminant late-onset sepsis in a neonatal intensive care unit 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 106, 1387–1390.PubMedCrossRefGoogle Scholar
  12. Karlowicz, M.G., Furigay, P.J., Croitoru, D.P., and Buescher, E.S. (2002). Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia. Pediatr. Infect. Dis. J. 21(1), 22–27.PubMedCrossRefGoogle Scholar
  13. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., and Donowitz, L.G. (2001). Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 345, 1660–1666.PubMedCrossRefGoogle Scholar
  14. Keyserling, H.L., Sinkowitz-Cochran, R.L., Harris, J.M. 2nd, Levine, G.L., Siegel, J.D., Stover, B.H. et al., and the Pediatric Prevention Network. (2003). Vancomycin use in hospitalized pediatric patients. Pediatrics 112(2), E104–E111.PubMedCrossRefGoogle Scholar
  15. Kicklighter, S.D., Springer, S.C., Cox, T., Hulsey, T.C., and Turner, R.B. (2001). Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 107, 293–298.PubMedCrossRefGoogle Scholar
  16. Nambiar, S. and Singh, N. (2002). Change in epidemiology of health care-associated infections in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 21, 839–842.PubMedCrossRefGoogle Scholar
  17. Patterson, J.E. (2002). Extended spectrum beta-lactamases: A therapeutic dilemma. Pediatr. Infect. Dis. J. 21, 957–959.PubMedCrossRefGoogle Scholar
  18. Rubin, L.G., Sánchez, P.J., Siegel, J., Levine, G., Saiman, L., Jarvis, W.R., and the Pediatric Prevention Network. (2002). Evaluation and treatment of neonates with suspected late-onset sepsis: A survey of neonatologists’ practices. Pediatrics 110(4), E42.PubMedCrossRefGoogle Scholar
  19. Saiman, L., Ludington, E., Dawson, J.D., Patterson, J.E., Rangel-Frausto, S., Wiblin, R.T. et al., and National Epidemiology of Mycoses Study Group. (2001). Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr. Infect. Dis. J. 20, 1119–1124.PubMedCrossRefGoogle Scholar
  20. Sánchez, P.J., Gard, J.W., Dao, R., Leos, N.K., and Perlman, J. (1998). Impact of a protocol for reduction of vancomycin use in a neonatal intensive care unit. The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego, CA.Google Scholar
  21. Sánchez, P.J., Mohamed, W.A., Gard, J.W., Gaffney, D., Byrd, L., Zeray, F., and Leos, N.K. (1999). Use of a vancomycin-reduction protocol in a neonatal intensive care unit: What’s the outcome? Presented at the 37th Annual Meeting of the Infectious Diseases Society of America, November 1999, Philadelphia, PA.Google Scholar
  22. Singh, N., Patel, K.M., Leger, M.M., Short, B., Sprague, B.M., Kalu, N., and Campos, J.M. (2002). Risk of resistant infections with Enterobacteriaceae in hospitalized neonates. Pediatr. Infect. Dis. J. 21, 1029–1033.PubMedCrossRefGoogle Scholar
  23. Stamos, J.K. and Rowley, A.H. (1995). Candidemia in a pediatric population. Clin. Infect. Dis. 20, 571–575.PubMedCrossRefGoogle Scholar
  24. Stoll, B.J., Hansen, N., Fanaroff, A.A., Wright, L.L., Carlo, W.A., Ehrenkranz, R.A. et al. (2002a). Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics 110, 285–291.PubMedCrossRefGoogle Scholar
  25. Stoll, B.J., Hansen, N., Fanaroff, A.A., Wright, L.L., Carlo, W.A., Ehrenkranz, R.A. et al. (2002b). Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N. Engl. J. Med. 347(4), 240–247.PubMedCrossRefGoogle Scholar
  26. Van Houten, M.A., Uiterwaal, C.S.P.M., Heesen, G.J.M., Arends, J.P., and Kimpen, J.L.L. (2001). Does the empiric use of vancomycin in pediatrics increase the risk for Gram-negative bacteremia? Pediatr. Infect. Dis. J. 20, 171–177.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Pablo J. Sánchez

There are no affiliations available

Personalised recommendations